Journal of Gastroenterology

, Volume 45, Issue 11, pp 1172–1182 | Cite as

Laparoscopic findings of reddish markings predict hepatocellular carcinoma in patients with hepatitis B virus-related liver disease

  • Bon Shoji
  • Fusao Ikeda
  • Shin-ichi Fujioka
  • Haruhiko Kobashi
  • Tetsuya Yasunaka
  • Yasuhiro Miyake
  • Hidenori Shiraha
  • Akinobu Takaki
  • Kazuhiro Nouso
  • Yoshiaki Iwasaki
  • Kazuhide Yamamoto
Original Article—Liver, Pancreas, and Biliary Tract

Abstract

Background

For patients with chronic hepatitis due to hepatitis B virus (HBV), factors predicting hepatocellular carcinoma (HCC) other than high levels of HBV-DNA and alanine aminotransferase (ALT) are needed to prevent HCC development, as many patients with chronic HBV infection fulfill these conditions. The purpose of this study was to clarify factors predictive of HCC development for those patients.

Methods

The study was a systematic cohort analysis of 303 consecutive patients with hepatitis B e-antigen, receiving laparoscopic examination for assessment of liver disease. Laparoscopic, histological, and clinical characteristics were investigated as related to HCC development.

Results

HCC occurred in 27 patients during a mean follow-up of 8.0 ± 5.0 years, at the age of 37–72 years. Significant associations with HCC development were shown for liver cirrhosis, histological activity grade, reddish markings, and older age. Multivariate analysis revealed that HCC development was strongly associated with older age and male gender (P = 0.002 and P = 0.043, respectively). HCC occurred more frequently in patients of age ≥30 years even with early stage than in patients of age <30 years (P = 0.031). Severe reddish markings, a laparoscopic finding of widespread parenchymal destruction, were highly associated with HCC development in patients of age ≥30 years at diagnosis (odds ratio = 1.67, P = 0.034), while histological activity grade and ALT level were not (P = 0.075 and P = 0.69, respectively).

Conclusions

HCC development is associated with older age, male gender, and liver cirrhosis. Reddish markings, rather than histological activity or ALT level, can be useful to predict HCC for HBV patients of age ≥30 years.

Keywords

Hepatitis B virus Hepatocellular carcinoma Laparoscopy 

Abbreviations

HBV

Hepatitis B virus

HCC

Hepatocellular carcinoma

ALT

Alanine aminotransferase

HCV

Hepatitis C virus

AST

Aspartate aminotransferase

References

  1. 1.
    Beasley RP, Hwang LY, Lin CC, et al. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet. 1981;2:1129–33.CrossRefPubMedGoogle Scholar
  2. 2.
    Liaw YF, Tai DI, Chu CM, et al. Early detection of hepatocellular carcinoma in patients with chronic type B hepatitis. A prospective study. Gastroenterology. 1986;90:263–7.PubMedGoogle Scholar
  3. 3.
    Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol. 2008;48:335–52.CrossRefPubMedGoogle Scholar
  4. 4.
    Tong MJ, Hsien C, Hsu L, et al. Treatment recommendations for chronic hepatitis B: an evaluation of current guidelines based on a natural history study in the United States. Hepatology. 2008;48:1070–8.CrossRefPubMedGoogle Scholar
  5. 5.
    Lai CL, Lok AS, Lin HJ, et al. Placebo-controlled trial of recombinant alpha 2-interferon in Chinese HBsAg-carrier children. Lancet. 1987;2:877–80.CrossRefPubMedGoogle Scholar
  6. 6.
    Orito E, Ichida T, Sakugawa H, et al. Geographic distribution of hepatitis B virus (HBV) genotype in patients with chronic HBV infection in Japan. Hepatology. 2001;34:590–4.CrossRefPubMedGoogle Scholar
  7. 7.
    Sumi H, Yokosuka O, Seki N, et al. Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease. Hepatology. 2003;37:19–26.CrossRefPubMedGoogle Scholar
  8. 8.
    Yang HI, Lu SN, Liaw YF, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med. 2002;347:168–74.CrossRefPubMedGoogle Scholar
  9. 9.
    Kalk H. Dienchronishen Verlaufsformen der Hepatitis epidemica in Beziehung zu ihren anatomischen Grudlagen. DMW. 1947;72:308–13.CrossRefGoogle Scholar
  10. 10.
    Kalk H, Wildhirt E. Lehrbuch und Atlas der Laparoskopie and Leberpunction. Stuttgart: Georg Thieme Verlag; 1962.Google Scholar
  11. 11.
    Poniachik J, Bernstein DE, Reddy KR, et al. The role of laparoscopy in the diagnosis of cirrhosis. Gastrointest Endosc. 1996;43:568–71.CrossRefPubMedGoogle Scholar
  12. 12.
    Cardi M, Muttillo IA, Amadori L, et al. Superiority of laparoscopy compared to ultrasonography in diagnosis of widespread liver diseases. Dig Dis Sci. 1997;42:546–8.CrossRefPubMedGoogle Scholar
  13. 13.
    Regev A, Berho M, Jeffers LJ, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol. 2002;97:2614–8.CrossRefPubMedGoogle Scholar
  14. 14.
    Arase Y, Suzuki F, Suzuki Y, et al. Potential of laparoscopy in chronic liver disease with hepatitis B and C viruses. Hepatol Res. 2008;38:877–85.CrossRefPubMedGoogle Scholar
  15. 15.
    Shiraki K, Shimizu A, Takase K, et al. Prospective study of laparoscopic findings with regard to the development of hepatocellular carcinoma in patients with hepatitis C virus-associated cirrhosis. Gastrointest Endosc. 2001;53:449–55.CrossRefPubMedGoogle Scholar
  16. 16.
    Shibayama T, Mori S, Ohtake H, et al. Risk factors of hepatocellular carcinoma in chronic hepatitis C and cirrhosis: special reference to laparoscopic findings. Dig Endosc. 1999;11:24–31.CrossRefGoogle Scholar
  17. 17.
    Desmet VJ, Gerber M, Hoofnagle JH, et al. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology. 1994;19:1513–20.CrossRefPubMedGoogle Scholar
  18. 18.
    Shimada N, Itoshima T, Ohta W, et al. A new classification of liver surface pictures by peritoneoscopic photography. Gastroenterol Endosc. 1971;13:68–76.Google Scholar
  19. 19.
    Watanabe M, Hirakawa H, Ikeda S, et al. Peritoneoscopy as an aid in intravenous injection of indocyanine green (ICG). Endoscopy. 1985;17:149–52.CrossRefPubMedGoogle Scholar
  20. 20.
    Ito T, Itoshima T, Ukida M, et al. Peritoneoscopy of the liver stained by intravenous injection of indocyanine green-experimental and clinical studies. Gastroenterol Jpn. 1983;18:593–8.PubMedGoogle Scholar
  21. 21.
    Michitaka K, Onji M, Horiike N, et al. Hepatitis B virus replication in dark reddish patchy markings appearing on the hepatic surface. Gastrointest Endosc. 1990;36:15–8.CrossRefPubMedGoogle Scholar
  22. 22.
    Kudo M. Imaging diagnosis of hepatocellular carcinoma and premalignant/borderline lesions. Semin Liver Dis. 1999;19:297–309.CrossRefPubMedGoogle Scholar
  23. 23.
    Peterson MS, Baron RL. Radiologic diagnosis of hepatocellular carcinoma. Clin Liver Dis. 2001;5:123–44.CrossRefPubMedGoogle Scholar
  24. 24.
    Ohta W. Significance of reddish asteroidal and meshwork markings on the liver surface of chronic hepatitis observed by peritoneoscopy-observation of liver cell necrosis in relation to the portal and hepatic veins. Acta Hepatol Jpn. 1975;16:448–63.Google Scholar
  25. 25.
    Shibayama T, Ohtake H, Hishima T. Formation and clinical significance of reddish markings on the liver surface: activity of chronic liver disease. Dig Endosc. 2003;15:100–7.CrossRefGoogle Scholar
  26. 26.
    Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997;349:825–32.CrossRefPubMedGoogle Scholar
  27. 27.
    Al-Chalabi T, Boccato S, Portmann BC, et al. Autoimmune hepatitis (AIH) in the elderly: a systematic retrospective analysis of a large group of consecutive patients with definite AIH followed at a tertiary referral centre. J Hepatol. 2006;45:575–83.CrossRefPubMedGoogle Scholar
  28. 28.
    Kubota J, Ikeda F, Terada R, et al. Mortality rate of patients with asymptomatic primary biliary cirrhosis diagnosed at age 55 years or older is similar to that of the general population. J Gastroenterol. 2009;44:1000–6.CrossRefPubMedGoogle Scholar
  29. 29.
    Piao CY, Fujioka S, Iwasaki Y, et al. Lamivudine treatment in patients with HBV-related hepatocellular carcinoma-using an untreated, matched control cohort. Acta Med Okayama. 2005;59:217–24.PubMedGoogle Scholar
  30. 30.
    Kuzuya T, Katano Y, Kumada T, et al. Efficacy of antiviral therapy with lamivudine after initial treatment for hepatitis B virus-related hepatocellular carcinoma. J Gastroenterol Hepatol. 2007;22:1929–35.CrossRefPubMedGoogle Scholar
  31. 31.
    Koda M, Matunaga Y, Kawakami M, et al. FibroIndex, a practical index for predicting significant fibrosis in patients with chronic hepatitis C. Hepatology. 2007;23:297–306.CrossRefGoogle Scholar
  32. 32.
    Ngo Y, Benhamou Y, Thibault V, et al. An accurate definition of the status of inactive hepatitis B virus carrier by a combination of biomarkers (FibroTest-ActiTest) and viral load. PLoS ONE. 2008;3:e2573.CrossRefPubMedGoogle Scholar

Copyright information

© Springer 2010

Authors and Affiliations

  • Bon Shoji
    • 1
  • Fusao Ikeda
    • 1
    • 2
  • Shin-ichi Fujioka
    • 3
  • Haruhiko Kobashi
    • 1
  • Tetsuya Yasunaka
    • 1
  • Yasuhiro Miyake
    • 1
    • 2
  • Hidenori Shiraha
    • 1
  • Akinobu Takaki
    • 1
  • Kazuhiro Nouso
    • 1
    • 2
  • Yoshiaki Iwasaki
    • 1
  • Kazuhide Yamamoto
    • 1
    • 2
  1. 1.Department of Gastroenterology and HepatologyOkayama University Graduate School of Medicine, Dentistry and Pharmaceutical SciencesOkayamaJapan
  2. 2.Department of Molecular HepatologyOkayama University Graduate School of Medicine, Dentistry and Pharmaceutical SciencesOkayamaJapan
  3. 3.Department of Internal MedicineOkayama Saiseikai General HospitalOkayamaJapan

Personalised recommendations